newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

  • MapLight Therapeutics announced that its Phase 2 ZEPHYR & IRIS clinical studies are progressing ahead of schedule.
  • Topline results for the ZEPHYR trial evaluating ML-007C-MA for schizophrenia are now expected in the third quarter of 2026.
  • The ZEPHYR trial is a randomized, double-blind, placebo-controlled study enrolling 300 hospitalized adults with acute psychosis exacerbation.
  • Accelerated enrollment in ZEPHYR allowed the company to narrow its timing guidance to Q3 2026.
  • Topline results for the Phase 2 IRIS trial evaluating ML-004 for autism spectrum disorder are also expected in the third quarter of 2026.
  • The IRIS trial is a double-blind, placebo-controlled study involving approximately 160 adult & adolescent participants.
  • MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for central nervous system disorders.